Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

MANF goes to work in Wolfram syndrome
October 2019
SHARING OPTIONS:

NEW YORK—The 79th Annual Scientific Sessions of the American Diabetes Association saw Amarantus Bioscience Holdings Inc. present data from in-vitro and animal studies of mesencephalic astrocyte-derived neurotrophic factor (MANF) in Wolfram syndrome. MANF has been found to activate proliferation of beta cells in WFS1 genetic animal models of Wolfram syndrome, suppress key apoptosis and protein misfolding and activate the pro-survival, pro-protein folding mTOR/S6K signaling pathway.
 
“MANF appears to have significant potential as a therapeutic agent for Wolfram syndrome,” said Stephanie Gebel, co-founder and chairman of the board at the Snow Foundation, a co-sponsor of the research. “Going forward, we will be working with Amarantus to help bring this exciting research into clinical development to help the pediatric patients who are affected by Wolfram syndrome.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.